Anti-NKG2A antibodies and compositions
This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
1. An anti-NKG2A antibody or an antigen-binding portion thereof, wherein said antibody comprises H-CDR1-3 and L-CDR1-3 amino acid sequences of:
a) SEQ ID NOs: 5-10, respectively;
b) SEQ ID NOs: 15-20, respectively;
c) SEQ ID NOs: 25-30, respectively;
d) SEQ ID NOs: 35-40, respectively;
e) SEQ ID NOs: 45-50, respectively; or
f) SEQ ID NOs: 55-60, respectively.
2. The antibody or antigen-binding portion of claim 1 , wherein said antibody comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of:
a) SEQ ID NOs: 3 and 4, respectively;
b) SEQ ID NOs: 13 and 14, respectively;
c) SEQ ID NOs: 23 and 24, respectively;
d) SEQ ID NOs: 33 and 34, respectively;
e) SEQ ID NOs: 43 and 44, respectively; or
f) SEQ ID NOs: 53 and 54, respectively.
3. The anti-NKG2A antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion has at least one property selected from:
a) binds to human NGK2A with a K D of 15 nM or less as measured by surface plasmon resonance;
b) binds to human NKG2A expressed on CHO-S cells;
c) blocks binding of HLA-E to human NKG2A/CD94 heterodimer expressed on CHO-S cells;
d) enhances NK-92 cell-mediated killing of K562 cells transfected with HLA-E;
e) enhances primary NK cell-mediated killing of K562 cells transfected with HLA-E;
f) enhances γδ T cell-mediated killing of K562 cells transfected with HLA-E; and
g) binds to a different epitope on human NKG2A than monalizumab.
4. An anti-NKG2A antibody that comprises:
a) a heavy chain (HC) comprising the amino acid sequences of SEQ ID NOs: 3 and 61 and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 4 and 62;
b) an HC comprising the amino acid sequences of SEQ ID NOs: 13 and 61 and an LC comprising the amino acid sequences of SEQ ID NOs: 14 and 62;
c) an HC comprising the amino acid sequences of SEQ ID NOs: 23 and 61 and an LC comprising the amino acid sequences of SEQ ID NOs: 24 and 62;
d) an HC comprising the amino acid sequences of SEQ ID NOs: 33 and 61 and an LC comprising the amino acid sequences of SEQ ID NOs: 34 and 62;
e) an HC comprising the amino acid sequences of SEQ ID NOs: 43 and 61 and an LC comprising the amino acid sequences of SEQ ID NOs: 44 and 62; or
f) an HC comprising the amino acid sequences of SEQ ID NOs: 53 and 61 and an LC comprising the amino acid sequences of SEQ ID NOs: 54 and 62.
5. A pharmaceutical composition comprising the anti-NKG2A antibody or antigen-binding portion of claim 1 and a pharmaceutically acceptable excipient.
6. The pharmaceutical composition of claim 5 , further comprising an immunostimulatory agent, a vaccine, a chemotherapeutic agent, an anti-neoplastic agent, an anti-angiogenic agent, or a tyrosine kinase inhibitor.
7. A bi-specific binding molecule comprising the antigen-binding domain of an anti-NKG2A antibody according to claim 1 and the antigen-binding domain of another, distinct antibody.
8. A method of using the anti-NKG2A antibody or antigen-binding portion of claim 1 in a diagnostic process comprising: (a) contacting a patient sample with said antibody or antigen-binding portion; and (b) detecting and/or measuring the level of NKG2A.
9. A method for enhancing immune activity in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody or antigen-binding portion of claim 1 .
10. A method for treating cancer in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody or antigen-binding portion of claim 1 .
11. The method of claim 10 , wherein the cancer is:
a) in a tissue selected from the group consisting of skin, lung, intestine, colon, ovary, brain, prostate, kidney, soft tissues, the hematopoietic system, head and neck, liver, bone, bladder, breast, stomach, uterus, cervix, and pancreas; or
b) head and neck cancer, breast cancer, colorectal cancer, lung cancer, esophageal cancer, acute myeloid leukemia, acute lymphoblastic leukemia, a myelodysplastic syndrome, multiple myeloma, chronic lymphoid leukemia, chronic myeloid leukemia, myeloproliferative neoplasm, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.
12. The method of claim 9 , further comprising administering to the patient an immunostimulatory agent, a vaccine, a chemotherapeutic agent, an anti-neoplastic agent, an anti-angiogenic agent, a tyrosine kinase inhibitor, or radiation therapy.
13. A method for treating an immune disorder in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody or antigen-binding portion of claim 1 .
14. An anti-NKG2A antibody that comprises a heavy chain (HC) comprising the amino acid sequences of SEQ ID NOs: 3 and 61 and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 4 and 62.
15. A pharmaceutical composition comprising the anti-NKG2A antibody of claim 14 and a pharmaceutically acceptable excipient.
16. A method of using the anti-NKG2A antibody or antigen-binding portion of claim 14 in a diagnostic process comprising: (a) contacting a patient sample with said antibody or antigen-binding portion; and (b) detecting and/or measuring the level of NKG2A.
17. A method for enhancing immune activity in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody of claim 14 .
18. The method of claim 17 , further comprising administering to the patient an immunostimulatory agent, a vaccine, a chemotherapeutic agent, an anti-neoplastic agent, an anti-angiogenic agent, a tyrosine kinase inhibitor, or radiation therapy.
19. A method for treating cancer in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody of claim 14 .
20. A method for treating an immune disorder in a human patient in need thereof, comprising administering to said patient a therapeutically effective amount of the anti-NKG2A antibody of claim 14 .